184 related articles for article (PubMed ID: 15650494)
1. Second-generation antipsychotic medications in children and adolescents.
Cheng-Shannon J; McGough JJ; Pataki C; McCracken JT
J Child Adolesc Psychopharmacol; 2004; 14(3):372-94. PubMed ID: 15650494
[TBL] [Abstract][Full Text] [Related]
2. Off-label second generation antipsychotics for impulse regulation disorders: a review.
Scheltema Beduin A; de Haan L
Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846
[TBL] [Abstract][Full Text] [Related]
3. Use of atypical antipsychotics in the treatment of autistic disorder.
Stachnik JM; Nunn-Thompson C
Ann Pharmacother; 2007 Apr; 41(4):626-34. PubMed ID: 17389666
[TBL] [Abstract][Full Text] [Related]
4. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.
Cohen D; Bonnot O; Bodeau N; Consoli A; Laurent C
J Clin Psychopharmacol; 2012 Jun; 32(3):309-16. PubMed ID: 22544019
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
6. A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics.
Lee ES; Vidal C; Findling RL
J Child Adolesc Psychopharmacol; 2018 Nov; 28(9):582-605. PubMed ID: 30312108
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects.
Roke Y; van Harten PN; Boot AM; Buitelaar JK
J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):403-14. PubMed ID: 19702492
[TBL] [Abstract][Full Text] [Related]
8. Use of antipsychotics in children and adolescents.
Findling RL; Steiner H; Weller EB
J Clin Psychiatry; 2005; 66 Suppl 7():29-40. PubMed ID: 16124839
[TBL] [Abstract][Full Text] [Related]
9. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
Maayan L; Correll CU
J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
[TBL] [Abstract][Full Text] [Related]
10. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
11. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.
Zuddas A; Zanni R; Usala T
Eur Neuropsychopharmacol; 2011 Aug; 21(8):600-20. PubMed ID: 21550212
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
[TBL] [Abstract][Full Text] [Related]
13. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials.
Jensen PS; Buitelaar J; Pandina GJ; Binder C; Haas M
Eur Child Adolesc Psychiatry; 2007 Mar; 16(2):104-20. PubMed ID: 17075688
[TBL] [Abstract][Full Text] [Related]
14. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses.
McConville BJ; Sorter MT
J Clin Psychiatry; 2004; 65 Suppl 6():20-9. PubMed ID: 15104523
[TBL] [Abstract][Full Text] [Related]
15. Treatments for late-life bipolar disorder.
Aziz R; Lorberg B; Tampi RR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):347-64. PubMed ID: 17296540
[TBL] [Abstract][Full Text] [Related]
16. Update and recommendations for the use of antipsychotics in early-onset psychoses.
Bryden KE; Carrey NJ; Kutcher SP
J Child Adolesc Psychopharmacol; 2001; 11(2):113-30. PubMed ID: 11436951
[TBL] [Abstract][Full Text] [Related]
17. Overdoses and ingestions of second-generation antipsychotics in children and adolescents.
Antia SX; Sholevar EH; Baron DA
J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):970-85. PubMed ID: 16379518
[TBL] [Abstract][Full Text] [Related]
18. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
Aman MG; Gharabawi GM;
J Clin Psychiatry; 2004 Sep; 65(9):1197-210. PubMed ID: 15367046
[TBL] [Abstract][Full Text] [Related]
19. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.
Correll CU
J Clin Psychiatry; 2008; 69 Suppl 4():26-36. PubMed ID: 18533766
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of atypical antipsychotics in mood disorders.
Yatham LN
J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S9-14. PubMed ID: 12832944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
